Ovarian Cancer: Latest Developments

Short summaries of recently published approvals, licensing and reimbursement regulations in Turkey, and notable studies in ovarian cancer. For general information about the disease, see the Ovarian Cancer page.

• • Turkey Licence (TİTCK)
  • Ovarian Cancer
  • 31 July 2026

  Mirvetuximab soravtansine received marketing authorisation in Turkey for folate receptor alpha-positive, platinum-resistant ovarian cancer

  According to TİTCK records, a product containing mirvetuximab soravtansine was licensed on 31.07.2026. According to the KÜB, the drug can be used as monotherapy in adults with folate receptor alpha (FRα)-positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have previously received one to three systemic treatment regimens. It is not suitable for use in primary platinum-refractory patients. Mirvetuximab soravtansine is an antibody-drug conjugate formed by attaching a chemotherapy molecule to an antibody that binds FRα. For eligibility, FRα expression must be demonstrated in the tumour tissue by testing. The KÜB carries a special warning for ocular toxicity; eye examination and protective eye drops are recommended before and during treatment.

  Status in Turkey: Mirvetuximab soravtansine is not on the SGK EK-4/A list (02.10.2026); its reimbursement status has not yet been clarified.

  • Source:
  • Approved KÜB, TİTCK
  • TİTCK List of Licensed Human Medicinal Products
• • FDA Approval
  • Ovarian Cancer
  • 25 March 2026

  Relacorilant receives FDA approval together with nab-paclitaxel in platinum-resistant ovarian cancer

  The FDA approved the glucocorticoid receptor antagonist relacorilant together with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three lines of systemic therapy, at least one of which included bevacizumab. In the ROSELLA trial, 381 patients were randomised to relacorilant plus nab-paclitaxel or nab-paclitaxel alone. Median progression-free survival was 6.5 versus 5.5 months (hazard ratio 0.70) and median overall survival 16 versus 11.9 months (hazard ratio 0.65). Because the drug reduces the effect of cortisone, it should not be used in patients who need to take a corticosteroid for a vital reason. Neutropenia and serious infections are among the main warnings.

  Status in Turkey: The TİTCK list of licensed products dated 02.10.2026 contains no product with relacorilant.

  • Source:
  • FDA announcement (25 March 2026)
• • FDA Approval
  • Ovarian Cancer
  • 10 February 2026

  Pembrolizumab receives FDA approval together with paclitaxel in PD-L1-positive platinum-resistant ovarian cancer

  The FDA approved pembrolizumab together with paclitaxel (with or without bevacizumab) in platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer whose tumour expresses PD-L1 (CPS 1 or higher) and who have previously received one or two lines of treatment. The KEYNOTE-B96 trial enrolled 643 patients. In 466 PD-L1-positive patients, median progression-free survival was 8.3 versus 7.2 months (hazard ratio 0.72) and median overall survival 18.2 versus 14.0 months (hazard ratio 0.76). PD-L1 testing is done with an approved diagnostic kit. Because treatment options in platinum-resistant ovarian cancer are limited, this result showing a survival difference is noteworthy. Warnings include immune-mediated adverse reactions.

  Status in Turkey: Pembrolizumab is licensed in Turkey for other indications; the licence and reimbursement status of this ovarian cancer use in Turkey has not yet been clarified.

  • Source:
  • FDA announcement (10 February 2026)

There are no developments to show for this selection. You can change the filters and try again.

The news on this page is for general information only; it is not a diagnosis or treatment recommendation. Whether a treatment is suitable for you is decided together with your physician after assessing the characteristics of your disease.